APWA
ALXN

Atlas Private Wealth Advisors’s Alexion Pharmaceuticals ALXN Stock Holding History

Atlas Private Wealth Advisors’s Portfolio ALXN Stock Details ALXN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q4 		– Sell
-200
Closed -$23K – 805
2020
Q3 		$23K Hold
200
– – 0.02% 293
2020
Q2 		$22K Buy
+200
New +$21.2K 0.02% 304

Other funds holding ALXN

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
ClearBridge Investments
ClearBridge Investments New York $121B AUM 27.52% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
LSV Asset Management
LSV Asset Management Chicago, Illinois $55.1B AUM 45.38% 1-Year Est. Return

Atlas Private Wealth Advisors's ALXN Position: Q4 2020 in Review

Atlas Private Wealth Advisors sold out of Alexion Pharmaceuticals (ALXN) in Q4 2020, closing a stake of 200 shares — an estimated $23K sold.

Atlas Private Wealth Advisors first reported a position in ALXN in Q2 2020 and held it in 2 quarters. The position peaked at $23K in Q3 2020. 827 funds tracked by Wall St. Rank hold ALXN as of Q4 2020.

  • Atlas Private Wealth Advisors reported no remaining Alexion Pharmaceuticals position as of Q4 2020 after selling out during the quarter.
  • Atlas Private Wealth Advisors sold 200 Alexion Pharmaceuticals shares in Q4 2020, an estimated $23K.
  • Atlas Private Wealth Advisors first reported a position in Alexion Pharmaceuticals in Q2 2020 and held it in 2 quarters.
  • Atlas Private Wealth Advisors's Alexion Pharmaceuticals position peaked at $23K in Q3 2020.
  • 827 funds tracked by Wall St. Rank held Alexion Pharmaceuticals as of Q4 2020.

Based on Atlas Private Wealth Advisors's 13F filing for Q4 2020, filed 29 Jan 2021.